Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 03, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) announced that a poster featuring updated data from the ongoing Phase 1 trial of FPA144 was presented today at the 2017 American Society of Clinical …